U.S. Congress - Highest Rated Blog Articles for S.1695 Biologics Price Competition and Innovation Act of 2007
S.1695 - Biologics Price Competition and Innovation Act of 2007
A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes. view all titles (2)
All Bill Titles
- Short: Biologics Price Competition and Innovation Act of 2007 as introduced.
- Official: A bill to amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, to promote innovation in the life sciences, and for other purposes. as introduced.
This Bill currently has no wiki content. If you would like to create a wiki entry for this bill, please Login, and then select the wiki tab to create it.
- Newest First
- Oldest First
- Highest Rated
Sort By
Patent Docs: Top Stories of 2008: #9 to #6
Five follow-on biologics bills were introduced during the 110th Congress: H.R. 1956 (which provides twelve years of data exclusivity and two years of market exclusivity), S. 1695 and H.R. 5629 (which provide four years of data ...
Patent Docs: Teva CEO Predicts Passage of Follow-on Biologics Bill ...
We also reported last summer that the Biotechnology Industry Organization (BIO) indicated that either H.R. 1956 (providing fourteen years of exclusivity), H.R. 5629 (providing twelve years of exclusivity), or S. 1695 (also providing ...
GoozNews: Biosimilars, Biogenerics Not the Same
Ted Kennedyâs S.1695, Sen. Judd Greggâs S.1505 and Rep. Anna Eshooâs H.R.5629 each call for testing drugs for safety, purity and âpotency.â The FDA uses potency as a synonym for efficacy. In other words, all three bills would manda
The Sietch Blog » General Motors: A Company That Deserves To Go Down
Bills targeted include: Climate change (S.2191), CAFE (H.R.5560, S.2555), Biogenerics Legislation (S.1695 et al), Railroad Antitrust Enforcement (H.R.1650, S.772), Ban Asbestos etc. Act (H.R.3339) â for other quarters, see individual ...
Patent Baristas » Economist Argues That 7 Years Ought to be Enough ...
S. 1695, sponsored by Senators Kennedy, Enzi, Clinton and Hatch, would allow for 12 years of data exclusivity. H.R. 5629, sponsored by Representatives Eshoo and Barton, would guarantee 12 years of data exclusivity, with an additional ...
General Motors: Emptying The Ocean With A Thimble
Bills targeted include: Climate change (S.2191), CAFE (HR5560, S.2555), Biogenerics Legislation (S.1695 et al), Railroad Antitrust Enforcement (HR1650, S.772), Ban Asbestos etc. Act (HR3339) â for other quarters, see individual links. ...
Bio Pharma Bonanza » Blog Archive » Economist Argues That 7 Years ...
S. 1695, sponsored by Senators Kennedy, Enzi, Clinton and Hatch, would allow for 12 years of data exclusivity. H.R. 5629, sponsored by Representatives Eshoo and Barton, would guarantee 12 years of data exclusivity, with an additional ...
HTA Blog: Waxman: FOBs Would Ensure Market Competition
which provides for 14 years; and S. 1695, introduced by Sens. Edward Kennedy (D-Mass.), Orrin Hatch (R-Utah), Michael Enzi (R-Wyo.) and Clinton, which favors 12 years of exclusivity. The periods of some of those generic biologic ...
Biosimilar Bill Reported From Senate Committee
Bipartisan legislation (S. 1695 (the Biologics Price Competition and Innovation Act)) that would create a mechanism for FDA approval of "biosimilar" (also referred to as "follow-on," "comparable," or "biogeneric") bi
Honores al Numero 1: Rafa Nadal
10th Wawrinka , S. 1695 Rafael Nadal Becomes 24th Player to Hold No. 1 Ranking Spaniard Rafael Nadal ascended to the No. 1 position in the South African Airways ATP Rankings on Monday by replacing his great rival Roger Federer of ...
Orange Book Blog: OBB News Briefs
On June 25, the Congressional Budget Office released a cost estimate for the Biologics Price Competition and Innovation Act of 2007 (S. 1695), concluding that the biosimilars bill would save American consumers $25 billion on ...
Federal Report Outlines Cost Savings in Biosimilars Approval Pathway
The Congressional Budget Office has released a report that provides a picture of the financial impact from the enaction of S.1695, the Biologics Price Competition and Innovation Act of 2007.
Federal Report Outlines Cost Savings in Biosimilars Approval Pathway
The Congressional Budget Office has released a report that provides a picture of the financial impact from the enaction of S.1695, the Biologics Price Competition and Innovation Act of 2007.
Federal Report Outlines Cost Savings in Biosimilars Approval Pathway
The Congressional Budget Office has released a report that provides a picture of the financial impact from the enaction of S.1695, the ?Biologics Price Competition and Innovation Act of 2007.?
FDALegislativeWatch: Biogenerics Get A Low Score From CBO, But Is ...
"By relying on the provisions in S. 1695, the CBO study also shows that we can achieve meaningful cost savings in biologics spending while providing needed protections to allow for continued innovation," Greenwood continued. ...
CBO Releases Report on Senate Follow-on Biologics Bill; BIO Calls ...
By Donald Zuhn -- Last week, the Congressional Budget Office (CBO) released a report on the Biologics Price Competition and Innovation Act (S. 1695), which would establish a pathway for the FDA to approve follow-on biologics. ...
Medical News Today News Alert
Legislation (S 1695) that would create an FDA approval pathway fo
Medical News Today News Alert
Legislation (S 1695) that would create an FDA approval pathway fo
CBO Savings Estimate For Follow-On Biologics Underscores Need For ...
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the Congressional Budget Office (CBO) report issued projecting cost savings from S. 1695, the Biologics Price ...
CBO Savings Estimate For Follow-On Biologics Underscores Need For ...
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the Congressional Budget Office (CBO) report issued projecting cost savings from S. 1695, the Biologics Price ...
CBO Savings Estimate for Follow-On Biologics, Biotechnology ...
"By relying on the provisions in S. 1695, the CBO study also shows that we can achieve meaningful cost savings in biologics spending while providing needed protections to allow for continued innovation. H.R. 1956, the Patient Protection ...
CBO: Biogenerics Would Save Federal Government $6.6 Billion Over ...
Enacting S. 1695 would reduce total expenditures on biologics in the United States Hidden List by $25 billion over the 2009-2018 period. â Enacting the bill would reduce budget deficits (or increase surpluses) ...
The Hill Blog» Blog Archive » Budget Estimate Confirms Biosimilar ...
The Congressional Budget Office (CBO) released a cost estimate yesterday of the âBiologics Price Competition and Innovation Act of 2007,â S. 1695, which the HELP Committee approved last year. CBO estimates that, if Congress enacts S. ...
PhRMA Issues Statement on Follow-On Biologics Legislation
âPhRMA thinks the cost estimate released by the Congressional Budget Office (CBO) of S. 1695 shows that it is possible to deliver cost savings to patients and the government through introduction of follow-on biologics while maintaining ...
CBO Savings Estimate for Follow-On Biologics Underscores Need for ...
... Budget Office (CBO) report issued today projecting cost savings from S. 1695, the Biologics Price Competition and Innovation Act of 2007: The CBO report shows that developing a pathway to review and approve follow-on biologics...
CBO: Biogenerics Would Save Government $6.6 Billion Over Decade
Enacting S. 1695 would reduce total expenditures on biologics in the United States Hidden List by $25 billion over the 2009-2018 period. -- Enacting the bill would reduce budget deficits (or increase surpluses) by a total of $6.6 ...
Biogenerics Would Save How Much? // Pharmalot
The bills, by the way, are S. 1695, the Biologics Price Competition and Innovation Act of 2007; H.R. 1956, the Patient Protection and Innovative Biologic Medicines Act of 2007; and H.R. 5629, the Pathway for Biosimilars Act. If you go ...
PCMA » CBO: Biogenerics Would Save Federal Government $6.6 Billion ...
Enacting S. 1695 would reduce total expenditures on biologics in the United States by $25 billion over the 2009- 2018 period. Enacting the bill would reduce budget deficits (or increase surpluses) by a total of $6.6 billion over the ...
CBO: Biogenerics Would Save Federal Government $6.6 Billion Over ...
Enacting S. 1695 would reduce total expenditures on biologics in the United States by $25 billion over the 2009- 2018 period. · Enacting the bill would reduce budget deficits (or increase surpluses) by a total of $6.6 billion over the ...
Cost savings from follow-on biologics
Enacting S. 1695 would reduce total expenditures on biologics in the United States by $0.2 billion over the 2009-2013 period and by about $25 billion over the 2009-2018 period. (Over that 10-year period, such savings would equal roughly ...
Bill's Views
- Today: 0
- Past Seven Days: 10
- All-Time: 978
-%
Users Support Bill
in favor / opposed-
Share This Bill
More Share via Email
